Caseware UK (AP4) 2022.0.179 2022.0.179 2023-03-312023-03-31true2022-04-01falseNo description of principal activity11trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07195985 2022-04-01 2023-03-31 07195985 2021-04-01 2022-03-31 07195985 2023-03-31 07195985 2022-03-31 07195985 c:CompanySecretary1 2022-04-01 2023-03-31 07195985 c:Director1 2022-04-01 2023-03-31 07195985 c:RegisteredOffice 2022-04-01 2023-03-31 07195985 d:ComputerEquipment 2022-04-01 2023-03-31 07195985 d:ComputerEquipment 2023-03-31 07195985 d:ComputerEquipment 2022-03-31 07195985 d:ComputerEquipment d:OwnedOrFreeholdAssets 2022-04-01 2023-03-31 07195985 d:Goodwill 2023-03-31 07195985 d:Goodwill 2022-03-31 07195985 d:CurrentFinancialInstruments 2023-03-31 07195985 d:CurrentFinancialInstruments 2022-03-31 07195985 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 07195985 d:CurrentFinancialInstruments d:WithinOneYear 2022-03-31 07195985 d:ShareCapital 2023-03-31 07195985 d:ShareCapital 2022-03-31 07195985 d:RetainedEarningsAccumulatedLosses 2023-03-31 07195985 d:RetainedEarningsAccumulatedLosses 2022-03-31 07195985 c:OrdinaryShareClass1 2022-04-01 2023-03-31 07195985 c:OrdinaryShareClass1 2023-03-31 07195985 c:OrdinaryShareClass1 2022-03-31 07195985 c:FRS102 2022-04-01 2023-03-31 07195985 c:AuditExempt-NoAccountantsReport 2022-04-01 2023-03-31 07195985 c:FullAccounts 2022-04-01 2023-03-31 07195985 c:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 07195985 2 2022-04-01 2023-03-31 xbrli:shares iso4217:GBP xbrli:pure


Registered number: 07195985












RICHARD REES RHEUMATOLOGY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

 

RICHARD REES RHEUMATOLOGY LIMITED

CONTENTS



Page
Company information
 
1
Balance sheet
 
2 - 3
Notes to the financial statements
 
4 - 9


 

RICHARD REES RHEUMATOLOGY LIMITED
 
COMPANY INFORMATION


Director
R G Rees 




Company secretary
J Rees



Registered number
07195985



Registered office
16 Great Queen Street
Covent Garden

London

WC2B 5AH




Accountants
Blick Rothenberg Limited
Chartered Accountants

16 Great Queen Street

Covent Garden

London

WC2B 5AH




Page 1


 
REGISTERED NUMBER:07195985
RICHARD REES RHEUMATOLOGY LIMITED

BALANCE SHEET
AS AT 31 MARCH 2023

2023
2022
Note
£
£

Fixed assets
  

Intangible assets
 4 
-
-

Tangible assets
 5 
2,044
149

  
2,044
149

Current assets
  

Debtors: amounts falling due within one year
 6 
7,685
12,613

Cash at bank and in hand
  
123,977
94,441

  
131,662
107,054

Creditors: amounts falling due within one year
 7 
(25,789)
(22,639)

Net current assets
  
 
 
105,873
 
 
84,415

Total assets less current liabilities
  
107,917
84,564

  

Net assets
  
107,917
84,564


Capital and reserves
  

Called up share capital 
 8 
100
100

Profit and loss account
  
107,817
84,464

Total equity
  
107,917
84,564


Page 2


 
REGISTERED NUMBER:07195985
RICHARD REES RHEUMATOLOGY LIMITED
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2023

The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed by the sole director: 




R G Rees
Director

Date: 22 November 2023

The notes on pages 4 to 9 form part of these financial statements.

Page 3

 

RICHARD REES RHEUMATOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

1.


General information

Richard Rees Rheumatology Limited is a private company limited by shares and registered in England & Wales. Its registered office is 16 Great Queen Street, Covent Garden, London, WC2B 5AH.
The financial statements are presented in Sterling (£), which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Going concern

After making enquiries, the director has a reasonable expectation that the company has adequate resources to continue in operational existence and meet its liabilities as they fall due for the foreseeable future, being a period of at least twelve months from the date these financial statements were approved. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Page 4

 

RICHARD REES RHEUMATOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

  
2.6

Financial instruments

The company has elected to apply Sections 11 and 12 of FRS 102 in respect of financial instruments.
Financial assets and financial liabilities are recognised when the company becomes party to the contractual provisions of the instrument. 
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
The company’s policies for its major classes of financial assets and financial liabilities are set out below. 
Financial assets
Basic financial assets, including trade and other debtors and cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.
Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.
Financial liabilities
Basic financial liabilities, including trade and other creditors, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
 
Page 5

 

RICHARD REES RHEUMATOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

Impairment of financial assets
Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account. 
For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the company would receive for the asset if it were to be sold at the reporting date. 
For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. 
If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.
Derecognition of financial assets and financial liabilities
Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions. 
Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires. 
Offsetting of financial assets and financial liabilities
Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

  
2.7

Share capital

Ordinary shares are classified as equity.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 6

 

RICHARD REES RHEUMATOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.10

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income.

 
2.11

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).


4.


Intangible assets




Goodwill

£



Cost


At 1 April 2022
89,020



At 31 March 2023

89,020



Amortisation


At 1 April 2022
89,020



At 31 March 2023

89,020



Net book value



At 31 March 2023
-



At 31 March 2022
-



Page 7

 

RICHARD REES RHEUMATOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

5.


Tangible fixed assets





Computer equipment

£



Cost


At 1 April 2022
2,380


Additions
2,023


Disposals
(1,208)



At 31 March 2023

3,195



Depreciation


At 1 April 2022
2,231


Charge for the year on owned assets
104


Disposals
(1,184)



At 31 March 2023

1,151



Net book value



At 31 March 2023
2,044



At 31 March 2022
149


6.


Debtors

2023
2022
£
£


Trade debtors
6,666
11,507

Prepayments and accrued income
1,019
1,106

7,685
12,613


Page 8

 

RICHARD REES RHEUMATOLOGY LIMITED

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Corporation tax
5,731
5,334

Other creditors
15,095
12,875

Accruals and deferred income
4,963
4,430

25,789
22,639



8.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



100 (2022 - 100) Ordinary shares of £1.00 each
100
100



9.


Related party transactions

Included in other creditors less than one year are amounts totalling £15,095 (2022 - £12,875) owed to the director of the company. These balances are interest free and repayable on demand.

 
Page 9